Acacia Pharma Group Plc
Acacia Pharma Group Plc
  • Home
  • Company
    • Overview
    • Strategy
    • Board
    • Management
  • Products
    • Overview
    • Therapeutic Areas
    • BARHEMSYS®
    • BYFAVO™
    • APD403
  • Partnering
  • Media
    • Press Releases
    • Events
  • Investors
    • Overview
    • Regulatory Announcements
    • Share Information
    • Share Price and Charts
    • Financial Reports and Presentations
    • Shareholder Meetings
    • Financial Calendar
    • Analysts
    • Corporate Governance
    • Warning for Shareholders
    • Subscribe for Updates
    • Prospectus Documents
  • Join Our Team
    • Current Openings
    • Our Cultural Hallmarks
    • US Employee Benefits
    • Staffing Agencies
  • Contact
  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • Site map
Acacia Pharma Group Plc
  • Home
  • Company
    • Overview
    • Strategy
    • Board
    • Management
  • Products
    • Overview
    • Therapeutic Areas
    • BARHEMSYS®
    • BYFAVO™
    • APD403
  • Partnering
  • Media
    • Press Releases
    • Events
  • Investors
    • Overview
    • Regulatory Announcements
    • Share Information
    • Share Price and Charts
    • Financial Reports and Presentations
    • Shareholder Meetings
    • Financial Calendar
    • Analysts
    • Corporate Governance
    • Warning for Shareholders
    • Subscribe for Updates
    • Prospectus Documents
  • Join Our Team
    • Current Openings
    • Our Cultural Hallmarks
    • US Employee Benefits
    • Staffing Agencies
  • Contact

Transforming medicine

Advancing care

Home > Investors > Financial Reports and Presentations

Investors > Financial Reports and Presentations

Acacia Pharma Corporate Presentation – Degroof Petercam Virtual Healthcare Conference, January 2021

Acacia Pharma Corporate Presentation September 2020

Interim Results for the Six Months ended 30 June 2020

US Approval of BYFAVO conference call presentation 

Acacia Pharma Group plc Annual Report and Financial Statements for the year ended 31 December 2019

Results for the Year Ended 31 December 2019

BARHEMSYS® approved by US FDA - 27 February 2020 

Cosmo Agreement - Conference Call Presentation 10 Jan 2020 

Interim Results 2019 Presentation

Interim Results for the Six Months ended 30 June 2019

Notice of 2019 AGM

2019 AGM Form of Proxy

Annual Report and Consolidated Financial Statements for the year ended 31 December 2018

Results for the year ended 31 December 2018

Unaudited Results for the nine months to 30 September 2018

Interim results for the First Half Year 2018

Annual Report and Consolidated Financial Statements for the year ended 31 December 2017

Investors

  • Overview
  • Regulatory Announcements
  • Share Information
  • Share Price and Charts
  • Financial Reports and Presentations
  • Shareholder Meetings
  • Financial Calendar
  • Analysts
  • Corporate Governance
  • Warning for Shareholders
  • Subscribe for Updates
  • Prospectus Documents

© 2021 Acacia Pharma Group Plc
(Registered in England and Wales No: 09759376)
Registered office address: The Officers’ Mess, Royston Road, Duxford, Cambridge CB22 4QH, UK

Acacia Pharma Limited (Registered in England and Wales No: 05934843) and Acacia Pharma Inc (Incorporated under the laws of Delaware, No: 5799660) are members of the Acacia Pharma Group

  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • Site map

Website by Instinctif Partners

By continuing to use acaciapharma.com you will be agreeing to the website Terms & Conditions, the Privacy Policy, and the use of Cookies.

By continuing to use acaciapharma.com you will be agreeing to the website Terms & Conditions, the Privacy Policy, and the use of Cookies.